Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for GeoVax Labs Inc. (GOVX : NSDQ)

• Company Description    GeoVax Labs Inc. is a clinical-stage biotechnology company. It engages in developing human vaccines against infectious diseases and cancer using a novel patented Modified Vaccinia Ankara-Virus Like Particle based vaccine platform. GeoVax Labs Inc. is based in ATLANTA, GA. Number of Employees: 19

• Price / Volume Information    Yesterday's Closing Price: $3.64 Daily Weekly Monthly 20 Day Moving Average: 12,055,546 shares Shares Outstanding: 3.47 (millions) Market Capitalization: $12.64 (millions) Beta: 3.36 52 Week High: $34.75 52 Week Low: $0.96 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 216.52% 201.06% 12 Week 127.50% 110.31% Year To Date -14.85% -40.86%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 1955 LAKE PARK DRIVE SUITE 300 - SMYRNA,GA 30080 USA ph: 678-384-7220 fax: 678-384-7281 investor@geovax.com http://www.geovax.com

• General Corporate Information    Officers David A. Dodd - President and Chief Executive Officer Mark W. Reynolds - Chief Financial Officer Randal D. Chase - Director Dean G. Kollintzas - Director Nicole Lemerond - Director Peer Information GeoVax Labs Inc. (CORR.) GeoVax Labs Inc. (RSPI) GeoVax Labs Inc. (CGXP) GeoVax Labs Inc. (BGEN) GeoVax Labs Inc. (GTBP) GeoVax Labs Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 373678705 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/26 Next Expected EPS Date: 07/27/26 Share - Related Items Shares Outstanding: 3.47 Most Recent Split Date: 1.00 (0.04:1) Beta: 3.36 Market Capitalization: $12.64 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-2.27 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-9.28 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 07/27/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 25.59 Price/Cash Flow: - Price / Sales: 2.06 EPS Growth vs. Year Ago Period: 76.71% vs. Previous Quarter: -% Sales Growth vs. Year Ago Period: 183.06% vs. Previous Quarter: -47.95% ROE 03/31/26 - -709.52 12/31/25 - -441.42 09/30/25 - -489.67 ROA 03/31/26 - -399.33 12/31/25 - -293.48 09/30/25 - -325.85 Current Ratio 03/31/26 - 1.06 12/31/25 - 2.74 09/30/25 - 3.57 Quick Ratio 03/31/26 - 1.06 12/31/25 - 2.74 09/30/25 - 3.57 Operating Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Net Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Pre-Tax Margin 03/31/26 - -2,508.10 12/31/25 - -862.40 09/30/25 - -755.26 Book Value 03/31/26 - 0.14 12/31/25 - 2.21 09/30/25 - 4.13 Inventory Turnover 03/31/26 - - 12/31/25 - - 09/30/25 - - Debt-to-Equity 03/31/26 - 0.00 12/31/25 - 0.00 09/30/25 - 0.00 Debt-to-Capital 03/31/26 - 0.00 12/31/25 - 0.00 09/30/25 - 0.00

Powered by Zacks Investment Research ©